VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the Virus-Like Particle and Nano-Particle Vaccines (“VLPNPV”) Conference on Friday, June 24 at 9:00 AM CEDT (3:00 AM ET). The event is being held at the Leiden University Medical Center in the Netherlands.
During the presentation, Customized Vaccine Design and Antigen Delivery through Novel Enveloped Virus-like Particles, Dr. Marc Kirchmeier, Ph.D., VBI’s Vice President of Formulation Development, will provide an overview of VBI’s eVLP Platform and will summarize recent developments in the company’s pipeline of eVLP Platform-derived vaccine candidates.VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines. eVLPs are an innovative new class of synthetic vaccines that closely mimic the target virus to elicit a potent immune response. eVLPs are highly customizable, which allows VBI to rationally design preventative or therapeutic vaccine candidates by controlling the expression of both surface and internal target proteins of interest. VBI is advancing a pipeline of eVLP vaccines with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”).
Now in its third year, the VLPNPV Conference attracts scientists and international researchers interested in virus-like particles, as well as contributors from academic programs and regulatory groups. For more information, visit: http://bit.ly/vlpnpv-2016.
- Event: 2016 Virus-Like Particle and Nano-Particle Vaccines Conference
- Date: Friday, June 24, 2016
- Time: 9:00 AM CEDT (3:00 AM ET)
- Location: Leiden University Medical Center in the Netherlands
- Event Website: http://bit.ly/vlpnpv-2016